nticoagulant therapy monitoring in COVID-19 patients in the intensive care unit: thromboelastometry and echocardiography
| Autor: | Yu. L. Ketsko, O. V. Tereshina |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Российский кардиологический журнал, Vol 27, Iss 1 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1560-4071 2618-7620 |
| DOI: | 10.15829/1560-4071-2022-4844 |
| Popis: | Aim. To determine the effectiveness of thromboelastometry (TEM) and echocardiography for anticoagulant therapy monitoring in patients with COVID-19.Material and methods. We analyzed treatment regimen of 92 patients with COVID-19. The patients were divided into two groups. In the control group (n=30), anticoagulant therapy with unfractionated heparin (UFH) was carried out under laboratory control of coagulation parameters. In the experimental group (n=62), anticoagulation was maintained by intravenous UFH under control of coagulation, echocardiography (Philips, Epiq 5) and TEM (ROTEM® delta). Echocardiography determined the pulmonary artery acceleration time (AT), mid-systolic notching (SN). The TEM method was used to study external (EXTEM) and internal (INTEM) pathways, differential tests (FIBTEM, HEPTEM) of coagulation. Statistical analysis was performed by calculating non-parametric statistics parameters, comparisons of differences in groups (Mann-Whitney test), area under the curve (AUC), and regression equations.Results. A high correlation level between echocardiographic and TEM parameters was determined. Their levels associated with a positive prognosis were calculated (AT>113,5 ms., AUC 0,979; p1,12%, AUC 0,971, p2,01%, AUC 0,941, p1,4%, AUC 0,934, p26 mm, AUC 0,954; p56,6 mm, AUC 0,938; p47,9 mm, AUC 0,838, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|